From Reuters.

Novo Nordisk said its experimental next-generation obesity drug CagriSema helped patients cut their weight by 22.7% in a late-stage trial, below the 25% it had expected, wiping as much as $125 billion off its market value.

#News #novonordisk #wegovyweightloss #ozempic #Reuters #Newsfeed

Read the story here: https://reut.rs/3P3SbbF

👉 Subscribe: http://smarturl.it/reuterssubscribe

Keep up with the latest news from around the world: https://www.reuters.com/
Follow Reuters on Facebook: https://www.facebook.com/Reuters
Follow Reuters on Twitter: https://twitter.com/Reuters
Follow Reuters on Instagram: https://www.instagram.com/reuters/?hl=en